ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2017
Association Between Treatment Facility Volume and Mortality of Patients With Multiple Myeloma.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Moving Mountains: Improving Access to Autologous Stem Cell Transplant for Vulnerable Patient Populations.Cancers · 2026Article
- Impact of social determinants of health on treatment patterns and outcomes in multiple myeloma.Future oncology (London, England) · 2025Article
- Multiple myeloma care, treatment patterns, and treatment durations in academic and community care settings.Future oncology (London, England) · 2025Observational
- Trends in mortality rates associated with multiple myeloma in the United States, 1999-2023.Frontiers in oncology · 2025Article
- Centralization of care for rare genetic syndromes associated with cancer: improving outcomes and advancing research on VHL disease.Nature reviews. Urology · 2024Review
- Disparities in relapsed or refractory multiple myeloma: recommendations from an interprofessional consensus panel.Blood cancer journal · 2024Review
- Radiation Facility Volume and Survival for Men With Very High-Risk Prostate Cancer Treated with Radiation and Androgen Deprivation Therapy.JAMA network open · 2023Article
- Integration of clinical features and sociodemographic factors: a simplified prognostic model for patients with multiple myeloma based on a double-center retrospective analysis.American journal of cancer research · 2023Article
- Socioeconomic status-based survival disparities and nomogram prediction for patients with multiple myeloma: Results from American and Chinese populations.Frontiers in oncology · 2022Article
- Orthopaedic Group Practice Size Is Increasing.Arthroscopy, sports medicine, and rehabilitation · 2021Article
- Tracing the potential of networks to improve community cancer care: an in-depth single case study.Implementation science communications · 2021Article
- Article
- Association of serum calcium levels with renal impairment and all-cause death in Chinese patients with newly diagnosed multiple myeloma: a cross-sectional, longitudinal study.Nutrition & metabolism · 2021Article
- Article
- Changes in treatment landscape of relapsed or refractory multiple myeloma and their association with mortality: Insights from German claims database.European journal of haematology · 2021Article
- Socioeconomic Status is Globally a Prognostic Factor for Overall Survival of Multiple Myeloma Patients: Synthesis of Studies and Review of the Literature.Mediterranean journal of hematology and infectious diseases · 2021Review
- Analysis of Radiation Facility Volume and Survival in Men With Lymph Node-Positive Prostate Cancer Treated With Radiation and Androgen Deprivation Therapy.JAMA network open · 2020Article
- Thirteen-year analyses of medical oncology outpatient day clinic data: a changing field.ESMO open · 2020Article
- COVID-19 and myeloma: what are the implications for now and in the future?British journal of haematology · 2020Article
- Economic impacts of care by high-volume providers for non-curative esophagogastric cancer: a population-based analysis.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2020Article
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose To determine the association between the number of patients with multiple myeloma (MM) treated annually at a treatment facility (volume) and all-cause mortality (outcome). Methods Using the National Cancer Database, we identified patients diagnosed with MM between 2003 and 2011. We classified the facilities by quartiles (Q; mean patients with MM treated per year): Q1: < 3.6; Q2: 3.6 to 6.1, Q3: 6.1 to 10.3, and Q4: > 10.3. We used random intercepts to account for clustering of patients within facilities and Cox regression to determine the volume-outcome relationship, adjusting for demographic (sex, age, race, ethnicity), socioeconomic (income, education, insurance type), geographic (area of residence, treatment facility location, travel distance), and comorbid (Charlson-Deyo score) factors and year of diagnosis. Results There were 94,722 patients with MM treated at 1,333 facilities. The median age at diagnosis was 67 years, and 54.7% were men. The median annual facility volume was 6.1 patients per year (range, 0.2 to 109.9). The distribution of patients according to facility volume was: Q1: 5.2%, Q2: 12.6%, Q3: 21.9%, and Q4: 60.3%. The unadjusted median overall survival by facility volume was: Q1: 26.9 months, Q2: 29.1 months, Q3: 31.9 months, and Q4: 49.1 months ( P < .001). Multivariable analysis showed that facility volume was independently associated with all-cause mortality. Compared with patients treated at Q4 facilities, patients treated at lower-quartile facilities had a higher risk of death (Q3 hazard ratio [HR], 1.12 [95% CI, 1.08 to 1.16]; Q2 HR, 1.17 [95% CI, 1.12 to 1.21]; Q1 HR, 1.22 [95% CI, 1.17 to 1.28]). Conclusion Patients who were treated for MM at higher-volume facilities had a lower risk of mortality compared with those who were treated at lower-volume facilities.
Indexed as
Identifiers
28199819What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.